Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19)
https://doi.org/10.14412/2074-2711-2021-2-65-72
Abstract
Objective: to investigate the effectiveness of long-term oral administration of Actovegin in post-COVID patients with cognitive impairment (CI).
Patients and methods. 444 patients (142 men, 302 women) with COVID-19 and CI participated in the study. One-half of the included participants – 222 patients (70 men and 152 women) – were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy; 222 patients (72 men and 150 women) were randomized to the control group. Cognitive functions were assessed with Montreal Cognitive Assessment (Montreal Cognitive Assessment test, МоСA test), fatigue – with Multidimensional Fatigue Inventory (MFI-20), emotional disturbances – with Spielberger-Hanin test.
Results and discussion. Post-COVID patients with CI in the Actovegin group after 60 days follow-up had higher mean MoCА scores (p<0.05), lower MFI (p<0.05), and Spielberger-Hanin test scores (p<0.05) compared to the control group.
Conclusion. Positive effect of Actovegin on the cognitive functions and emotional state of post-COVID patients with CI was observed.
About the Author
V. A. Kutashov
N.N. Burdenko Voronezh State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
10, Studencheskaya St., Voronezh 394036, Russia
References
1. Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). Versiya 10 (08.02.2021)» (utv. Minzdravom Rossii) [Interim guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 10 (02/08/2021)» (approved by the Ministry of Health of Russia)]. Available from: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/Временные_МР_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf (In Russ.).
2. Kutashov VA, Dutova TI, Banin IN, et al. Damage to the nervous system in patients with a new coronavirus infection (clinical observation). Vselennaya mozga = Universe of the Brain. 2020;2(4(7)):23-8 (In Russ.).
3. Heneka MT, Golenbock D, Latz E, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020 Jun 4;12(1):69. doi: 10.1186/s13195-020-00640-3
4. Paterson RW, Brown RL, Benjamin L. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020 Oct 1;143(10):3104-20. doi: 10.1093/brain/awaa240
5. Gusev EI, Martynov MYu, Boyko AN, et al. New coronavirus infection (COVID-19) and damage to the nervous system: mechanisms of neurological disorders, clinical manifestations, organization of neurological care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = Journal of Neurology and Psychiatry. S.S. Korsakov. 2020;120(6):7-16. doi: 10.17116/jnevro20201200617 (In Russ.).
6. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683-90. doi: 10.1001/jamaneurol.2020.1127
7. Hernandez-Fernandez F, Sandoval Valencia H, Barbella-Aponte RA, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020 Oct 1;143(10):3089-103. doi: 10.1093/brain/awaa239
8. Lindlau A, Widmann CN, Putensen C, et al. Predictors of hippocampal atrophy in critically ill patients. Eur J Neurol. 2015 Feb;22(2):410-5. doi: 10.1111/ene.12443. Epub 2014 Apr 12.
9. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010 Oct 27;304(16):1787-94. doi: 10.1001/jama.2010.1553
10. Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis. Lancet Neurol. 2014 Jun;13(6):630-6. doi: 10.1016/S1474-4422(14)70017-1
11. Girard T, Thompson J, Pandharipande P, et al. Clinical phenotypes of delirium during critical illness and severity of subsequent longterm cognitive impairment: a prospective cohort study. Lancet Respir Med. 2018 Mar;6(3):213-22. doi: 10.1016/S2213-2600(18)30062-6
12. Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care. 2019 Nov 12;23(1):352. doi: 10.1186/s13054-019-2626-z
13. Konyaeva VV. Encephalopathy Associated with COVID-19: Experience of Clinical Observations in Practical Work of Neurologist. Lechebnoye delo = General Medicine. 2020;(3):43-6. doi: 10.24412/2071-5315-2020-12255 (In Russ.).
14. Fedorovich AA, Soboleva GN. Microcirculation in patients with arterial hypertension, coronary heart disease and cognitive impairment on treatment with Actovegin. Regionarnoye krovoobrashcheniye i mikrotsirkulyatsiya = Regional Blood Circulation and Microcirculation. 2015;14(3):40-51. doi: 10.24884/1682-6655-2015-14-3-40-51 (In Russ.).
15. Tanashyan MM, Shabalina AA, Lagoda OV, etc. Multimodal approach to the correction of neurological manifestations of chronic brain ischemia. Terapevticheskiy arkhiv = Therapeutic archive. 2018;(12):61-7. doi: 10.26442/00403660.2018.12.000010 (In Russ.).
16. Kovalchuk VV. The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):57-66. doi: 10.14412/2074- 2711-2021-1-57-66 (In Russ.).
17. Wade DT. Rehabilitation after COVID-19: an evidence-based approach. Clin Med (Lond). 2020 Jul;20(4):359-65. doi: 10.7861/clinmed.2020-0353. Epub 2020 Jun 9.
18. Boriskina LM. Actovegin in the treatment of patients with cognitive impairment in chronic cerebral ischemia. Nervno-myshechnyye bolezni. 2015;5(4):25-31. doi: 10.17650/2222-8721-2015-5-4-25-31 (In Russ.).
19. Mikhaylova NM, Selezneva ND, Kalyn YaB, et al. The effectiveness of Actovegin treatment in elderly patients with a syndrome of mild cognitive decline in vascular genesis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2013;113(7-2):69-76. Available from: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2/2013/7/031997-72982013728 (In Russ.).
20. Zakharov VV, Sosina VB. Possibilities of antihypoxants in the treatment of moderate cognitive impairments in patients with diabetes mellitus. Lechashchiy vrach. 2010;(3):87-91. Available from: https://www.elibrary.ru/item.asp?id=21546938 (In Russ.).
21. Kol'tsova EA. The use of Actovegin for the prevention of cognitive impairment after a stroke. Farmateka. 2018;5(358):66-70. Available from: https://www.elibrary.ru/item.asp?id=34998854 (In Russ.).
22. Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International DoubleBlind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017 May;48(5):1262-70. doi: 10.1161/STROKEAHA.116.014321
23. Kanowski S, Kinzler E, Lehmann E, et al. Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry. 1995 Jul;28(4):125-33. doi: 10.1055/s-2007-979604
24. Belopasov VV, Yashu Ya, Samoylova EM, Baklaushev VP. Damage to the nervous system in COVID-19. Klinicheskaya praktika. 2020;11(2):60-80. doi: 10.17816/clinpract34851 (In Russ.).
Review
For citations:
Kutashov V.A. Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19). Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):65-72. (In Russ.) https://doi.org/10.14412/2074-2711-2021-2-65-72
Views: 1531
Email this article 